Successful treatment of pityriasis rubra pilaris with risankizumab, a IL-23/p19 antagonist

J Eur Acad Dermatol Venereol. 2023 Jan;37(1):e106-e109. doi: 10.1111/jdv.18516. Epub 2022 Aug 23.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Humans
  • Pityriasis Rubra Pilaris* / drug therapy

Substances

  • risankizumab
  • Antibodies, Monoclonal